Mutagenesis, Vol. 17, No. 5, 431-438,
September 2002
© 2002 UK Environmental Mutagen Society/Oxford University Press
Oestrogens induce G1 arrest in benzo[a]pyrene-treated MCF-7 breast cells whilst enhancing genotoxicity and clonogenic survival
Department of Biological Sciences, I.E.N.S., Lancaster University, Lancaster LA1 4YQ, UK
Carcinogens, such as benzo[a]pyrene (B[a]P), allow cells to evade G1 arrest (the stealth property), thus increasing the chance that DNA damage will ultimately result in transformation. In this study we have investigated the effects of B[a]P in MCF-7 cells incubated in the presence or absence of oestrogens (ß-oestradiol, oestrone or oestriol). The cytokinesis block micronucleus assay was used to examine cells for chromosomal damage. Micronuclei were scored in 500 binucleate cells per treatment. Increased micronucleus formation (3-fold) occurred following 24 h treatment with 10–6 M B[a]P alone. Following co-treatment with either 10–9 M ß-oestradiol, 10–8 M oestrone or 10–8 M oestriol, 2- to 3-fold increases in micronuclei were observed with 10–8 M B[a]P. When MCF-7 cells were pre-incubated for 96 h with 10–9 M ß-oestradiol, 10–8 M oestrone or 10–8 M oestriol prior to the addition of B[a]P for 24 h, up to a 5-fold enhanced sensitivity to micronucleus formation was observed with ß-oestradiol and oestrone, while oestriol appeared to reduce levels of micronucleus formation. B[a]P-induced decreases in cell proliferation (per cent binucleate cells) and plating efficiency were reversed by all three oestrogens. Analysis of cell cycle distributions revealed that treatment with oestrogens or B[a]P alone did not induce marked effects on cell cycle distributions. However, in combination oestrogen and B[a]P induced increases in G0/G1, decreases in S phase and increases in G2/M. This work suggests that whilst oestrogens appear to enhance carcinogen-induced DNA damage, they also appear, paradoxically, to trigger mechanisms that facilitate clonogenic survival, which may be relevant to breast cancer initiation.
1 To whom correspondence should be addressed. Tel: +44 1524 594505; Fax: +44 1524 843854; Email: f.martin{at}lancaster.ac.uk
2 The first two authors contributed equally to this study
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  A. Kabil, E. Silva, and A. Kortenkamp Estrogens and genomic instability in human breast cancer cells--involvement of Src/Raf/Erk signaling in micronucleus formation by estrogenic chemicals Carcinogenesis, October 1, 2008; 29(10): 1862 - 1868. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Jiao, S. L. Allinson, M. J. Walsh, R. Hewitt, K. J. Cole, D. H. Phillips, and F. L. Martin Growth kinetics in MCF-7 cells modulate benzo[a]pyrene-induced CYP1A1 up-regulation Mutagenesis, March 1, 2007; 22(2): 111 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. L. Barber, M. J. Walsh, R. Hewitt, K. C. Jones, and F. L. Martin Low-dose treatment with polybrominated diphenyl ethers (PBDEs) induce altered characteristics in MCF-7 cells Mutagenesis, September 1, 2006; 21(5): 351 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Hammiche, M. J. German, R. Hewitt, H. M. Pollock, and F. L. Martin Monitoring Cell Cycle Distributions in MCF-7 Cells Using Near-Field Photothermal Microspectroscopy Biophys. J., May 1, 2005; 88(5): 3699 - 3706. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. L. Martin and K. T. Semple Environmental health impacts: occurrence, exposure and significance, Lancaster University, UK, 9-10 September 2003 Mutagenesis, September 1, 2004; 19(5): 423 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. I. Kalantzi, R. Hewitt, K. J. Ford, L. Cooper, R. E. Alcock, G. O. Thomas, J. A. Morris, T. J. McMillan, K. C. Jones, and F. L. Martin Low dose induction of micronuclei by lindane Carcinogenesis, April 1, 2004; 25(4): 613 - 622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Stopper, E. Schmitt, C. Gregor, S. O. Mueller, and W. H. Fischer Increased cell proliferation is associated with genomic instability: elevated micronuclei frequencies in estradiol-treated human ovarian cancer cells Mutagenesis, May 1, 2003; 18(3): 243 - 247. [Abstract] [Full Text] [PDF]
|
|